Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
4
Neutral
5
Bullish
5
Bearish
27
Neutral
5
Bullish
14
Bearish
23
Neutral
0
Bullish
9
Bearish
4
Neutral
5
Bullish
5
Bearish
4
Neutral
5
Bullish
5
Bearish
23
Neutral
0
Bullish
9
Bearish
23
Neutral
0
Bullish
9
Bearish
23
Neutral
0
Bullish
9
Investor Presentation
Q1 FY21
Everest Organics Ltd is primarily engaged in the manufacturing of Active Pharmaceutical Ingredients and intermediaries, with operations commencing in 1993.
The company had set up a plant in Andhra Pradesh focusing initially on bulk drugs and formulations, with a public issue in 1995 to fund its growth.
In 1996, Everest Organics expanded its production capabilities with increased capacity for ciprofloxacin and benzimidazole, illustrating strategic adjustments to market conditions.
Despite initial plans for PHPG manufacturing, the company shifted focus towards enhancing ciprofloxacin production due to changing market dynamics.
Through strategic investments, the company introduced new products like Esomeprazole Magnesium in 2007-08, highlighting innovation in its product portfolio.
Pharmaceuticals & Biotechnology
Pharmaceuticals
272 Cr
Moderate Risk
51.8
37.7
-2.9
3.4
536.40
197.00
Sales CAGR
Profit CAGR
ROE
ROCE
Everest Organics Ltd (EVERESTO) is currently trading at 273.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Everest Organics Ltd is primarily engaged in the manufacturing of Active Pharmaceutical Ingredients and intermediaries, with operations commencing in 1993. The company had set up a plant in Andhra Pradesh focusing initially on bulk drugs and formulations, with a public issue in 1995 to fund its growth. In 1996, Everest Organics expanded its production capabilities with increased capacity for ciprofloxacin and benzimidazole, illustrating strategic adjustments to market conditions. Despite initial plans for PHPG manufacturing, the company shifted focus towards enhancing ciprofloxacin production due to changing market dynamics. Through strategic investments, the company introduced new products like Esomeprazole Magnesium in 2007-08, highlighting innovation in its product portfolio.
Over the past 52 weeks, Everest Organics Ltd has traded between a low of ₹197.00 and a high of ₹536.40. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Everest Organics Ltd has a market capitalization of approximately 269.89. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Everest Organics Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 51.31 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 269.89 Cr, Everest Organics Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Everest Organics Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Everest Organics Ltd is 51.31. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Everest Organics Ltd’s Board meeting is scheduled for August 14, 2026.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
525.00 | 302 Cr | 25.82 | 3.99 | 0.95 | 14.04 | 19.30 | 11.82 | ||
96.15 | 300 Cr | 71.91 | 1.80 | 0.00 | 2.64 | 5.20 | 1.40 | ||
81.50 | 295 Cr | -31.41 | 3.17 | 0.00 | -10.86 | -6.04 | -5.37 | ||
46.22 | 282 Cr | -112.04 | 2.97 | 0.00 | -1.13 | 4.36 | -2.27 | ||
11.50 | 279 Cr | 13.51 | 1.25 | 0.00 | 8.29 | 9.09 | 5.92 | ||
267.90 | 270 Cr | 51.31 | 3.40 | 0.00 | 7.35 | 11.62 | 2.19 | ||
12.25 | 239 Cr | 16.61 | 0.41 | 0.00 | -9.85 | -8.75 | -39.42 | ||
| Median: 7 Co. | — | 81.50 | 282 Cr | 16.61 | 2.97 | 0.00 | 2.64 | 5.20 | 1.40 |
